Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Congestive Heart Failure (Heart Failure)-Pipeline Review, H1 2015

Congestive Heart Failure (Heart Failure)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Congestive Heart Failure (Heart Failure)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Congestive Heart Failure (Heart Failure)-Pipeline Review, H1 2015', provides an overview of the Congestive Heart Failure (Heart Failure)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Congestive Heart Failure (Heart Failure) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Congestive Heart Failure (Heart Failure) Overview 11

Therapeutics Development 12

Pipeline Products for Congestive Heart Failure (Heart Failure)-Overview 12

Pipeline Products for Congestive Heart Failure (Heart Failure)-Comparative Analysis 13

Congestive Heart Failure (Heart Failure)-Therapeutics under Development by Companies 14

Congestive Heart Failure (Heart Failure)-Therapeutics under Investigation by Universities/Institutes 20

Congestive Heart Failure (Heart Failure)-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Congestive Heart Failure (Heart Failure)-Products under Development by Companies 25

Congestive Heart Failure (Heart Failure)-Products under Investigation by Universities/Institutes 32

Congestive Heart Failure (Heart Failure)-Companies Involved in Therapeutics Development 34

Acorda Therapeutics, Inc. 34

Amgen Inc. 35

Anexon, Inc. 36

AnGes MG, Inc. 37

Angion Biomedica Corp. 38

ARCA biopharma, Inc. 39

Ascelegen Therapeutics, Inc. 40

Asklepios BioPharmaceutical, Inc. 41

Athersys, Inc. 42

Bayer AG 43

BEAT BioTherapeutics Corp. 44

Bial-Portela & Ca, S.A. 45

Bioheart, Inc. 46

BioLineRx, Ltd. 47

Bristol-Myers Squibb Company 48

Cardio3 BioSciences SA 49

Cardioxyl Pharmaceuticals, Inc. 50

Celladon Corporation 51

Cellmid Limited 52

FibroGen, Inc. 53

GlaxoSmithKline plc 54

Glucox Biotech AB 55

Innopharmax Inc. 56

Jiangsu Hengrui Medicine Co., Ltd. 57

Juventas Therapeutics, Inc. 58

Laboratoires Pierre Fabre SA 59

Lead Pharma Holding B.V. 60

Lee's Pharmaceutical Holdings Limited 61

Les Laboratoires Servier SAS 62

Lonestar Heart, Inc. 63

Mast Therapeutics, Inc. 64

Merck & Co., Inc. 65

Mesoblast Limited 66

Mezzion Pharma Co. Ltd. 67

MI.TO. Technology S.r.L. 68

miRagen Therapeutics, Inc. 69

NeoStem, Inc. 70

Novartis AG 71

Nyken BV 72

Ono Pharmaceutical Co., Ltd. 73

Palatin Technologies, Inc. 74

Pfizer Inc. 75

PharmaIN Corporation 76

PhaseBio Pharmaceuticals, Inc. 77

Pluristem Therapeutics Inc. 78

QUANTUM GENOMICS Corp. 79

Recardio GmbH 80

RedHill Biopharma Ltd. 81

RegenoCELL Therapeutics, Inc. 82

Sanofi 83

Stemedica Cell Technologies, Inc. 84

Target Heart Biotec Srl 85

Torrent Pharmaceuticals Limited 86

Trevena, Inc. 87

uniQure N.V. 88

Vicore Pharma AB 89

Zensun (Shanghai) Sci & Tech Co., Ltd. 90

Congestive Heart Failure (Heart Failure)-Therapeutics Assessment 91

Assessment by Monotherapy Products 91

Assessment by Combination Products 92

Assessment by Target 93

Assessment by Mechanism of Action 97

Assessment by Route of Administration 101

Assessment by Molecule Type 103

Drug Profiles 105

(sacubitril + valsartan)-Drug Profile 105

AdipoCell-Drug Profile 107

AdipoCell + MyoCell-Drug Profile 109

aladorian-Drug Profile 110

aliskiren fumarate-Drug Profile 112

AMR-001-Drug Profile 114

ANG-3557-Drug Profile 116

ANG-4011-Drug Profile 117

AntimiR-199a-Drug Profile 118

ANX-042-Drug Profile 119

ARX-720-Drug Profile 120

BAY-1067197-Drug Profile 121

BAY-1142524-Drug Profile 122

BBR-12-Drug Profile 123

beperminogene perplasmid-Drug Profile 124

BIA-51058-Drug Profile 129

BNP-CHF-Drug Profile 130

BR-5489-Drug Profile 131

bucindolol hydrochloride-Drug Profile 132

C-21-Drug Profile 134

C3BSCQR-1-Drug Profile 136

CAP-1002-Drug Profile 138

CARD-024-Drug Profile 140

carvedilol CR-Drug Profile 142

carvedilol CR-Drug Profile 143

carvedilol phosphate ER-Drug Profile 144

cenderitide-Drug Profile 145

CGEN-856-Drug Profile 147

cimaglermin alfa-Drug Profile 149

CM-1-Drug Profile 151

CMK-103-Drug Profile 153

CTX-101-Drug Profile 154

CTX-201-Drug Profile 155

CXL-1036-Drug Profile 156

CXL-1427-Drug Profile 157

Drug for Heart Failure-Drug Profile 158

Drug to Inhibit Calpain for Heart Failure-Drug Profile 159

Drugs to Inhibit miR-425 for Hypertension and Heart Failure-Drug Profile 160

F-373280-Drug Profile 161

FG-6874-Drug Profile 162

FG-8205-Drug Profile 163

finerenone-Drug Profile 164

Gene Therapy for Congestive Heart Failure-Drug Profile 165

Gene Therapy for Ischemic Heart Failure-Drug Profile 166

Gene Therapy to Activate AC-6 for Congestive Heart Failure-Drug Profile 167

Gene Therapy to Activate S100-A1 for Congestive Heart Failure-Drug Profile 168

Gene Therapy to Activate S100-A1 for Heart Failure-Drug Profile 169

Gene Therapy to Activate UCn 2 for Congestive Heart Failure-Drug Profile 170

Gene Therapy to Inhibit GRK2 for Heart Failure-Drug Profile 171

Gene Therapy to Inhibit Mef2 for Heart Failure-Drug Profile 172

GSK-2798745-Drug Profile 173

GSK-2881078-Drug Profile 174

istaroxime-Drug Profile 175

ITD-1-Drug Profile 177

ivabradine-Drug Profile 178

ivabradine SR-Drug Profile 180

JVS-100-Drug Profile 181

Mesenchymal Stem Cells-Drug Profile 183

MGN-9103-Drug Profile 185

MicroRNAs for Heart Failure-Drug Profile 186

MK-7145-Drug Profile 187

MP-3167-Drug Profile 188

MPC-150IM-Drug Profile 189

MTP-131-Drug Profile 191

MultiStem-Drug Profile 193

Mydicar-Drug Profile 196

MyoCell-Drug Profile 198

Neucardin-Drug Profile 199

NYK-1112-Drug Profile 202

omecamtiv mecarbil-Drug Profile 203

ONO-4232-Drug Profile 206

PB-1046-Drug Profile 207

PGC Based Natriuretic Peptides-Drug Profile 209

PL-3994-Drug Profile 210

poloxamer-Drug Profile 212

Protein for Diastolic Heart Failure-Drug Profile 214

pyroglutaminated serpinin-Drug Profile 215

QGC-101-Drug Profile 216

REC-02-Drug Profile 217

Recombinant Protein for Congestive Heart Failure-Drug Profile 218

rivaroxaban-Drug Profile 219

RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases-Drug Profile 224

RNAi Oligonucleotide to Inhibit STIM1 for Cardiovascular Disorders-Drug Profile 226

S-38844-Drug Profile 227

SAR-296968-Drug Profile 228

serelaxin-Drug Profile 229

serpinin-Drug Profile 232

SG-1002-Drug Profile 233

sildenafil citrate-Drug Profile 234

Small Molecule for Heart Failure-1-Drug Profile 236

Small Molecule for Heart Failure-2-Drug Profile 237

Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure-Drug Profile 238

Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders-Drug Profile 239

Small Molecule to Inhibit NOX-4 for Heart Failure-Drug Profile 240

Small Molecules for Diabetes and Congestive Heart Failure-Drug Profile 241

Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis-Drug Profile 242

Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure-Drug Profile 243

Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain-Drug Profile 244

Small Molecules to Inhibit PDE4 for Heart Failure-Drug Profile 245

Small Molecules to Inhibit PDE5 for Ischemia Reperfusion Injury-Drug Profile 246

Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Metabolic Syndrome and Heart Failure-Drug Profile 247

Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders-Drug Profile 248

sodium nitrite-Drug Profile 249

SP-20202-Drug Profile 251

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 252

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 254

Stem Cell Therapy for Chronic Heart Failure-Drug Profile 255

Stem Cell Therapy for Heart failure-Drug Profile 256

Stem Cell Therapy for Heart Failure-Drug Profile 257

TRC-4186-Drug Profile 258

TRV-027-Drug Profile 260

TRV-120023-Drug Profile 262

udenafil-Drug Profile 263

ularitide-Drug Profile 265

vepoloxamer-Drug Profile 266

vericiguat-Drug Profile 267

XEN-105-Drug Profile 268

Congestive Heart Failure (Heart Failure)-Recent Pipeline Updates 269

Congestive Heart Failure (Heart Failure)-Dormant Projects 343

Congestive Heart Failure (Heart Failure)-Discontinued Products 351

Congestive Heart Failure (Heart Failure)-Product Development Milestones 353

Featured News & Press Releases 353

Appendix 361

Methodology 361

Coverage 361

Secondary Research 361

Primary Research 361

Expert Panel Validation 361

Contact Us 361

Disclaimer 362

List of Tables

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2015 20

Number of Products under Development for Congestive Heart Failure (Heart Failure)-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 23

Number of Products under Development by Companies, H1 2015 (Contd..1) 24

Number of Products under Development by Companies, H1 2015 (Contd..2) 25

Number of Products under Development by Companies, H1 2015 (Contd..3) 26

Number of Products under Development by Companies, H1 2015 (Contd..4) 27

Number of Products under Investigation by Universities/Institutes, H1 2015 29

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Development, H1 2015 32

Products under Development by Companies, H1 2015 33

Products under Development by Companies, H1 2015 (Contd..1) 34

Products under Development by Companies, H1 2015 (Contd..2) 35

Products under Development by Companies, H1 2015 (Contd..3) 36

Products under Development by Companies, H1 2015 (Contd..4) 37

Products under Development by Companies, H1 2015 (Contd..5) 38

Products under Development by Companies, H1 2015 (Contd..6) 39

Products under Investigation by Universities/Institutes, H1 2015 40

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 41

Congestive Heart Failure (Heart Failure)-Pipeline by Acorda Therapeutics, Inc., H1 2015 42

Congestive Heart Failure (Heart Failure)-Pipeline by Amgen Inc., H1 2015 43

Congestive Heart Failure (Heart Failure)-Pipeline by Anexon, Inc., H1 2015 44

Congestive Heart Failure (Heart Failure)-Pipeline by AnGes MG, Inc., H1 2015 45

Congestive Heart Failure (Heart Failure)-Pipeline by Angion Biomedica Corp., H1 2015 46

Congestive Heart Failure (Heart Failure)-Pipeline by ARCA biopharma, Inc., H1 2015 47

Congestive Heart Failure (Heart Failure)-Pipeline by Ascelegen Therapeutics, Inc., H1 2015 48

Congestive Heart Failure (Heart Failure)-Pipeline by Asklepios BioPharmaceutical, Inc., H1 2015 49

Congestive Heart Failure (Heart Failure)-Pipeline by Athersys, Inc., H1 2015 50

Congestive Heart Failure (Heart Failure)-Pipeline by Bayer AG, H1 2015 51

Congestive Heart Failure (Heart Failure)-Pipeline by BEAT BioTherapeutics Corp., H1 2015 52

Congestive Heart Failure (Heart Failure)-Pipeline by Bial-Portela & Ca, S.A., H1 2015 53

Congestive Heart Failure (Heart Failure)-Pipeline by Bioheart, Inc., H1 2015 54

Congestive Heart Failure (Heart Failure)-Pipeline by BioLineRx, Ltd., H1 2015 55

Congestive Heart Failure (Heart Failure)-Pipeline by Bristol-Myers Squibb Company, H1 2015 56

Congestive Heart Failure (Heart Failure)-Pipeline by Cardio3 BioSciences SA, H1 2015 57

Congestive Heart Failure (Heart Failure)-Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015 58

Congestive Heart Failure (Heart Failure)-Pipeline by Celladon Corporation, H1 2015 59

Congestive Heart Failure (Heart Failure)-Pipeline by Cellmid Limited, H1 2015 60

Congestive Heart Failure (Heart Failure)-Pipeline by FibroGen, Inc., H1 2015 61

Congestive Heart Failure (Heart Failure)-Pipeline by GlaxoSmithKline plc, H1 2015 62

Congestive Heart Failure (Heart Failure)-Pipeline by Glucox Biotech AB, H1 2015 63

Congestive Heart Failure (Heart Failure)-Pipeline by Innopharmax Inc., H1 2015 64

Congestive Heart Failure (Heart Failure)-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 65

Congestive Heart Failure (Heart Failure)-Pipeline by Juventas Therapeutics, Inc., H1 2015 66

Congestive Heart Failure (Heart Failure)-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 67

Congestive Heart Failure (Heart Failure)-Pipeline by Lead Pharma Holding B.V., H1 2015 68

Congestive Heart Failure (Heart Failure)-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 69

Congestive Heart Failure (Heart Failure)-Pipeline by Les Laboratoires Servier SAS, H1 2015 70

Congestive Heart Failure (Heart Failure)-Pipeline by Lonestar Heart, Inc., H1 2015 71

Congestive Heart Failure (Heart Failure)-Pipeline by Mast Therapeutics, Inc., H1 2015 72

Congestive Heart Failure (Heart Failure)-Pipeline by Merck & Co., Inc., H1 2015 73

Congestive Heart Failure (Heart Failure)-Pipeline by Mesoblast Limited, H1 2015 74

Congestive Heart Failure (Heart Failure)-Pipeline by Mezzion Pharma Co. Ltd., H1 2015 75

Congestive Heart Failure (Heart Failure)-Pipeline by MI.TO. Technology S.r.L., H1 2015 76

Congestive Heart Failure (Heart Failure)-Pipeline by miRagen Therapeutics, Inc., H1 2015 77

Congestive Heart Failure (Heart Failure)-Pipeline by NeoStem, Inc., H1 2015 78

Congestive Heart Failure (Heart Failure)-Pipeline by Novartis AG, H1 2015 79

Congestive Heart Failure (Heart Failure)-Pipeline by Nyken BV, H1 2015 80

Congestive Heart Failure (Heart Failure)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 81

Congestive Heart Failure (Heart Failure)-Pipeline by Palatin Technologies, Inc., H1 2015 82

Congestive Heart Failure (Heart Failure)-Pipeline by Pfizer Inc., H1 2015 83

Congestive Heart Failure (Heart Failure)-Pipeline by PharmaIN Corporation, H1 2015 84

Congestive Heart Failure (Heart Failure)-Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 85

Congestive Heart Failure (Heart Failure)-Pipeline by Pluristem Therapeutics Inc., H1 2015 86

Congestive Heart Failure (Heart Failure)-Pipeline by QUANTUM GENOMICS Corp., H1 2015 87

Congestive Heart Failure (Heart Failure)-Pipeline by Recardio GmbH, H1 2015 88

Congestive Heart Failure (Heart Failure)-Pipeline by RedHill Biopharma Ltd., H1 2015 89

Congestive Heart Failure (Heart Failure)-Pipeline by RegenoCELL Therapeutics, Inc., H1 2015 90

Congestive Heart Failure (Heart Failure)-Pipeline by Sanofi, H1 2015 91

Congestive Heart Failure (Heart Failure)-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 92

Congestive Heart Failure (Heart Failure)-Pipeline by Target Heart Biotec Srl, H1 2015 93

Congestive Heart Failure (Heart Failure)-Pipeline by Torrent Pharmaceuticals Limited, H1 2015 94

Congestive Heart Failure (Heart Failure)-Pipeline by Trevena, Inc., H1 2015 95

Congestive Heart Failure (Heart Failure)-Pipeline by uniQure N.V., H1 2015 96

Congestive Heart Failure (Heart Failure)-Pipeline by Vicore Pharma AB, H1 2015 97

Congestive Heart Failure (Heart Failure)-Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015 98

Assessment by Monotherapy Products, H1 2015 99

Assessment by Combination Products, H1 2015 100

Number of Products by Stage and Target, H1 2015 102

Number of Products by Stage and Mechanism of Action, H1 2015 106

Number of Products by Stage and Route of Administration, H1 2015 110

Number of Products by Stage and Molecule Type, H1 2015 112

Congestive Heart Failure (Heart Failure) Therapeutics-Recent Pipeline Updates, H1 2015 277

Congestive Heart Failure (Heart Failure)-Dormant Projects, H1 2015 351

Congestive Heart Failure (Heart Failure)-Dormant Projects (Contd..1), H1 2015 352

Congestive Heart Failure (Heart Failure)-Dormant Projects (Contd..2), H1 2015 353

Congestive Heart Failure (Heart Failure)-Dormant Projects (Contd..3), H1 2015 354

Congestive Heart Failure (Heart Failure)-Dormant Projects (Contd..4), H1 2015 355

Congestive Heart Failure (Heart Failure)-Dormant Projects (Contd..5), H1 2015 356

Congestive Heart Failure (Heart Failure)-Dormant Projects (Contd..6), H1 2015 357

Congestive Heart Failure (Heart Failure)-Dormant Projects (Contd..7), H1 2015 358

Congestive Heart Failure (Heart Failure)-Discontinued Products, H1 2015 359

Congestive Heart Failure (Heart Failure)-Discontinued Products (Contd..1), H1 2015 360

List of Figures

Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2015 20

Number of Products under Development for Congestive Heart Failure (Heart Failure)-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 22

Number of Products under Investigation by Universities/Institutes, H1 2015 28

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Products, H1 2015 32

Assessment by Monotherapy Products, H1 2015 99

Assessment by Combination Products, H1 2015 100

Number of Products by Top 10 Targets, H1 2015 101

Number of Products by Stage and Top 10 Targets, H1 2015 101

Number of Products by Top 10 Mechanism of Actions, H1 2015 105

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 105

Number of Products by Top 10 Routes of Administration, H1 2015 109

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 110

Number of Products by Top 10 Molecule Types, H1 2015 111

Number of Products by Stage and Top 10 Molecule Types, H1 2015 111

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acorda Therapeutics, Inc.

Amgen Inc.

Anexon, Inc.

AnGes MG, Inc.

Angion Biomedica Corp.

ARCA biopharma, Inc.

Ascelegen Therapeutics, Inc.

Asklepios BioPharmaceutical, Inc.

Athersys, Inc.

Bayer AG

BEAT BioTherapeutics Corp.

Bial - Portela & Ca, S.A.

Bioheart, Inc.

BioLineRx, Ltd.

Bristol-Myers Squibb Company

Cardio3 BioSciences SA

Cardioxyl Pharmaceuticals, Inc.

Celladon Corporation

Cellmid Limited

FibroGen, Inc.

GlaxoSmithKline plc

Glucox Biotech AB

Innopharmax Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Juventas Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Lead Pharma Holding B.V.

Lee's Pharmaceutical Holdings Limited

Les Laboratoires Servier SAS

Lonestar Heart, Inc.

Mast Therapeutics, Inc.

Merck & Co., Inc.

Mesoblast Limited

Mezzion Pharma Co. Ltd.

MI.TO. Technology S.r.L.

miRagen Therapeutics, Inc.

NeoStem, Inc.

Novartis AG

Nyken BV

Ono Pharmaceutical Co., Ltd.

Palatin Technologies, Inc.

Pfizer Inc.

PharmaIN Corporation

PhaseBio Pharmaceuticals, Inc.

Pluristem Therapeutics Inc.

QUANTUM GENOMICS Corp.

Recardio GmbH

RedHill Biopharma Ltd.

RegenoCELL Therapeutics, Inc.

Sanofi

Stemedica Cell Technologies, Inc.

Target Heart Biotec Srl

Torrent Pharmaceuticals Limited

Trevena, Inc.

uniQure N.V.

Vicore Pharma AB

Zensun (Shanghai) Sci & Tech Co., Ltd.

Congestive Heart Failure (Heart Failure) Therapeutic Products under Development, Key Players in Congestive Heart Failure (Heart Failure) Therapeutics, Congestive Heart Failure (Heart Failure) Pipeline Overview, Congestive Heart Failure (Heart Failure) Pipeline, Congestive Heart Failure (Heart Failure) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com